Armata Pharmaceuticals Inc (ARMP) - Total Liabilities
Based on the latest financial reports, Armata Pharmaceuticals Inc (ARMP) has total liabilities worth $295.48 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Armata Pharmaceuticals Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Armata Pharmaceuticals Inc - Total Liabilities Trend (1993–2025)
This chart illustrates how Armata Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Armata Pharmaceuticals Inc's balance sheet.
Armata Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Armata Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bohai Water Industry Co Ltd
SHE:000605
|
China | CN¥5.21 Billion |
|
Parrot
PA:PARRO
|
France | €46.30 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €51.15 Million |
|
Berjaya Land Bhd
KLSE:4219
|
Malaysia | RM11.44 Billion |
|
Hoasen Group
VN:HSG
|
Vietnam | ₫10.34 Trillion |
|
Trifork Holding AG
CO:TRIFOR
|
Denmark | Dkr164.52 Million |
|
Jiangsu Jingxue Insulation
SHE:301010
|
China | CN¥558.96 Million |
|
iHeartMedia Inc Class A
NASDAQ:IHRT
|
USA | $6.86 Billion |
Liability Composition Analysis (1993–2025)
This chart breaks down Armata Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ARMP equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.84 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Armata Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Armata Pharmaceuticals Inc (1993–2025)
The table below shows the annual total liabilities of Armata Pharmaceuticals Inc from 1993 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $295.48 Million | +119.76% |
| 2024-12-31 | $134.46 Million | +3.09% |
| 2023-12-31 | $130.43 Million | +81.66% |
| 2022-12-31 | $71.80 Million | +61.81% |
| 2021-12-31 | $44.37 Million | +114.78% |
| 2020-12-31 | $20.66 Million | +90.27% |
| 2019-12-31 | $10.86 Million | +218.14% |
| 2018-12-31 | $3.41 Million | +0.18% |
| 2017-12-31 | $3.41 Million | -59.79% |
| 2016-12-31 | $8.47 Million | -54.89% |
| 2015-12-31 | $18.78 Million | -25.42% |
| 2014-12-31 | $25.18 Million | -51.73% |
| 2013-12-31 | $52.17 Million | +471.52% |
| 2012-12-31 | $9.13 Million | +110.81% |
| 2011-12-31 | $4.33 Million | +370.65% |
| 2009-12-31 | $920.00K | -91.58% |
| 2008-12-31 | $10.92 Million | -10.72% |
| 2007-12-31 | $12.23 Million | +1.11% |
| 2006-12-31 | $12.10 Million | -33.61% |
| 2005-12-31 | $18.23 Million | -9.78% |
| 2004-12-31 | $20.20 Million | -13.82% |
| 2003-12-31 | $23.44 Million | -49.11% |
| 2002-12-31 | $46.07 Million | +36.95% |
| 2001-12-31 | $33.64 Million | +37.06% |
| 2000-12-31 | $24.54 Million | +266.31% |
| 1999-12-31 | $6.70 Million | +59.52% |
| 1998-12-31 | $4.20 Million | 0.00% |
| 1997-12-31 | $4.20 Million | -25.00% |
| 1996-12-31 | $5.60 Million | +33.33% |
| 1995-12-31 | $4.20 Million | +10.53% |
| 1994-12-31 | $3.80 Million | +100.00% |
| 1993-12-31 | $1.90 Million | -- |
About Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudo… Read more